HTLV-I/II Prevalence in Different Geographic Locations

Transfusion Medicine Reviews

Volumn 18, Issue 1, 2004, Pages 46-57

  Vrielink, Hans ^a   Reesink, Henk W ^a  

^a Sanquin Bloedbank Regio Noordwest Amsterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASIA; BLOOD DONOR; BLOOD TRANSFUSION; CARIBBEAN ISLANDS; CENTRAL AFRICA; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMIGRANT; INTRAVENOUS DRUG ABUSE; JAPAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SCREENING TEST; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOUTH AMERICA; SPASTIC PARESIS; T CELL LEUKEMIA; UNITED STATES; UVEITIS; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0346250847     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2003.10.004     Document Type: Article

References (127)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77:7415-7419, 1980
2. Hjelle B: Human T-cell leukemia/lymphoma viruses: Lifecycle, pathogenicity, epidemiology and diagnosis. Arch Pathol Lab Med 15:440-450, 1991
3. Lee HH, Swanson P, Rosenblatt JD, et al: Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 337:1435-1439, 1991
4. Feigenbaum F, Fang C, Sandler SG: Human T-lymphotropic virus type-II in Panamanian Guaymi Indians. Transfusion 34:158-161, 1994
5. Maloney EM, Biggar RJ, Neel JV, et al: Endemic human T-cell lymphotropic virus type-II infection among isolated Brazilian Amerindians. J Inf Dis 166:100-107, 1992
6. Gessain A, Fretz C, Koulibaly M, et al: Evidence of HTLV-II infection in Guinea, West Africa. J Acq Immune Defic Synd Hum Retrov 6:324-325, 1993
7. Madeleine MM, Wiktor SZ, Goedert IJ, et al: HTLV-I and HTLV-II world-wide distribution: Reanalysis of 4,832 immunoblot results. Int J Cancer 54:255-260, 1993
8. Seiki M, Hattori S, Yoshida M: Human adult T-cell leukemia virus: Molecular cloning of the provirus DNA and the unique terminal structure. Proc Natl Acad Sci U S A 79:6899-6902, 1982
9. Okochi K, Sato H, Hinuma Y: A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: Seroconversion in recipients. Vox Sang 46:245-253, 1994
10. Centers for Disease Control and Prevention and the USPHS Working Group: Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann Int Med 118:448-454, 1993
11. Manns A, Wilks RJ, Murphy EL, et al: A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 51:886-891, 1992
12. Nelson KE, Donahue JG, Munoz A, et al: Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: A multicenter study of HIV-I and HTLV-I/II infections. Ann Intern Med 117:554-559, 1992
13. Bittencourt AL: Vertical transmission of HTLV-I/II: A review. Rev Inst Med Trop Sao Paulo 40:245-251, 1998
14. Manns A, Hisada M, La Grenade L: Human T-lymphotropic virus type I infection. Lancet 353:1951-1958, 1999
15. Bittencourt AL, Sabino EC, Costa MC, et al: No evidence of vertical transmission of HTLV-I in bottle-fed children. Rev Inst Med Trop Sao Paulo 44:63-65, 2002
16. Hall WW, Ishak R, Zhu SW, et al: Human T lymphotropic virus type II (HTLV-II): Epidemiology, molecular properties, and clinical features of infection. J Acq Immune Defic Synd Hum Retrov 13 S204-S214; 1996 (suppl)
17. Richardson JH, Edwards AI, Cruickshank JK, et al: In vivo cellular tropism of human T-cell leukemia virus type I. J Virol 64:5682-5687, 1990
18. Inaba S, Sato H, Okochi K, et al: Prevention of transmission of human T-lymphotropic virus type I (HTLV-I) through transfusion, by donor screening with antibody to the virus. Transfusion 29:7-11, 1989
19. Inaba S, Okochi K, Sato H, et al: Efficacy of donor screening for HTLV-I and the natural history of transfusion transmitted infection. Transfusion 39:1104-1110, 1999
20. Kusuhara K, Sonoda S, Takahashi K, et al: Mother-to-child transmission of human T-cell leukemia virus type I (HTLV-I): A fifteen-year follow-up in Okinawa, Japan. Int J Cancer 40:755-757, 1987
21. Hino S, Katamine S, Miyata H, et al: Primary prevention of HTLV-I in Japan. J Acq Immune Defic Synd Hum Retrov 13:S199-S203, 1996 (suppl)
22. Van den Burg PJM, Vrielink H, Reesink HW: Time interval of 5 years between HTLV-I infection and the appearance of antibodies in a repeat blood donor. Transfusion 38: S191, 1998 (suppl, abstr)
23. Madeleine MM, Wiktor SZ, Goedert IJ, et al: HTLV-I and HTLV-II world-wide distribution: Reanalysis of 4,832 immunoblot results. Int J Cancer 54:255-260, 1993
24. Watanabe T, Mochizuki M, Yamaguchi K: HTLV-I uveitis (HU). Leukemia 11:582-584, 1997 (suppl)
25. Nakao K, Ohba N: HTLV-I associated uveitis revisited: Characteristic grey-white granular deposits on retinal vessels. Br J Ophthalmol 80:719-722, 1996
26. Takatsuki K, Uchiyama T, Sagawa K, et al: Adult T-Cell Leukemia in Japan. Topics in Hematology. Amsterdam, Excerpta Medica, 1977, pp 73-77
27. Seiki M, Hattori S, Yoshida M: Human adult T-cell leukemia virus: Molecular cloning of the provirus DNA and the unique terminal structure. Proc Natl Acad Sci U S A 79:6899-6902, 1982
28. Uchiyama T, Yodoi J, Sagawa K, et al: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50:481-492, 1977
29. Bartholomew C, Jack N, Edwards J, et al: HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. J Hum Virol 1:302-305, 1998
30. Takatsuki K, Matsuoka M, Yamaguchi K: Adult T-cell leukemia in Japan. J Acq Immune Defic Synd Hum Retrov 13:S15-S19, 1996 (suppl)
31. Murphy EL, Friday J, Smith JW, et al: High prevalence of HTLV-associated myelopathy (HAM) among subjects infected with HTLV-I and -II. Transfusion 33:S263, 1993 (suppl, abstr)
32. Taylor GP, Tosswill JHC, Matutes E, et al: Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acq Imm Defic Synd 22:92-100, 1999
33. Gessain A, Gout O: Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Int Med 117:933-946, 1992
34. Anderson DW, Epstein JS, Lairmore MD, et al: Serological confirmation of human T-cell lymphotropic virus type I infection in healthy blood and plasma donors. Blood 74:2585-2591, 1989
35. Dodd RY. Adverse consequences of blood transfusion: Quantitative estimates, in, Nance ST (ed): Blood Supply: Risks, Perceptions and Prospects for the Future. Bethesda, MD. American Association of Blood Banks, 1994, pp 1-24
36. Manns A, Hisada M, La Grenade L: Human T-lymphotropic virus type I infection. Lancet 353:1951-1958, 1999
37. Osame M, Janssen R, Kubota H, et al: Nationwide survey of HTLV-I associated myelopathy in Japan: Association with blood transfusion. Ann Neurol 25:50-56, 1990
38. Jacobson S: Cellular immune responses to HTLV-I: Immunopathogenic role in HTLV-I associated neurologic disease. J Acq Immune Defic Synd Hum Retrov 13:S100-S106, 1996 (suppl)
39. Inaba S, Okochi K, Sato H, et al: Efficacy of donor screening for HTLV-I and the natural history of transfusion transmitted infection. Transfusion 39:1104-1110, 1999
40. Hisada M, Okayama A, Shioiri S, et al: Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 92:3557-3561, 1998
41. Kira J-I, Koyanagi Y, Hamakado T, et al: HTLV-II in patients with HTLV-I associated myelopathy. Lancet 338:64-65, 1991
42. Shimotohno K, Takahashi Y, Shimizu N, et al: Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame for the protease gene. Proc Natl Acad Sci U S A 82:3101-3105, 1985
43. Kalyanararnan VS, Samgadharan MG, Robert-Guroff M, et al: A new subtype of human T-lymphotropic virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218:571-575, 1992
44. Hjelle B, Appenzeller O, Mills R, et al: Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 339:645-646, 1992
45. Murphy EL, Engstom JW, Miller K, et al: HTLV-II associated myelopathy in 43-year-old woman. Lancet 341:757-758, 1993
46. Wiktor SZ, Pate EJ, Weiss SH, et al: Sensitivity of HTLV-I antibody assays for HTLV-II. Lancet 338:512-513, 1991
47. Hjelle B, Wilson C, Cyrus S, et al: Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors. Blood 81:1641-1644, 1993
48. Rios M, Khabbaz RF, Kaplan JE, et al: Transmission of HTLV-II by HTLV-I screened blood products. Transfusion 33 S260, 1993 (suppl, abstr)
49. Manns A, Blattner WA: The epidemiology of the human T-cell lymphotropic virus type I and type II: Etiologic role in human disease. Transfusion 31:67-75, 1991
50. North ML, Lemaire JM, Couroucé JAM, et al: Performance of kits for the detection of anti-HTLV-I/II antibodies commercialized in France in 1995. J Acq Immune Defic Synd Hum Retrov 10:254, 1995 (abstr)
51. Vrielink H, Reesink HW, Zaaijer HL, et al: Sensitivity and specificity of four anti-human T-cell lymphotropic virus type I or type I/II assays. Transfusion 36:344-347, 1996
52. Vrielink H, Reesink HW, Habibuw M, et al: Comparison of four HTLV-I and HTLV-I+II ELISAs. Vox Sang 76:187-191, 1999
53. Roberts BD, Foung SKH, Lipka IJ, et al: Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic viruses types I and II. J Clin Microbiol 31:260-264, 1993
54. Brodine SK, Kairne EM, Roberts C, et al: Simultaneous confirmation and differentiation of human T-lymphotropic viruses types I and II infection by modified Western blot containing recombinant envelope glycoproteins. Transfusion 33:925-929, 1993
55. Zaaijer HL, Cuypers HTM, Dudok de Wit C, et al: Results of I-year screening of donors in The Netherlands for human T-lymphotropic virus (HTLV) type I: Significance of Western blot pattern for confirmation of HTLV infection. Transfusion 34:877-880, 1994
56. Andersson S, Tynell E, Lithander E, et al: Results of a one year screening of Swedish blood donors for HTLV. J Acq Immune Defic Synd Hum Retrov 10:251, 1995 (abstr)
57. Christiansen CB: Experience with one year of blood donor screening for HTLV-I/II in Denmark. J Acq Immune Defic Synd Hum Retrov 10:251, 1995 (abstr)
58. Leite F, Mota AP, Monteiro R, et al: The interpretation of human T leukemia virus indeterminate Western blot patterns. J Acq Immune Defic Synd Hum Retrov 10:254, 1995 (abstr)
59. Vrielink H, Zaaijer HL, van der Poel CL, et al: New strip immunoblot for the confirmation of HTLV-I/II infection. Vox Sang 70:114-116, 1996
60. Sabino EC, Zrein M, Tabora CP, et al: Evaluation of the Inno-Lia HTLV-I/II assay for confirmation of human T-cell leukemia virus-reactive sera in blood bank donations. J Clin Microbiol 37:1324-1328, 1999
61. Garin B, Gosselin S, de Thé G, et al: HTLV-I/II infection in a high viral endemic area of Zaire, Central Africa: Comparative evaluation of serology, PCR, and significance of indeterminate Western blot pattern. J Med Virol 44:104-109, 1994
62. Kleinman S, Swanson P, Allain JP, Lee H: Transfusion transmission of human T-lymphotropic virus types I an II: Serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 33:14-18, 1993
63. Dodd RY, Notari EP IV, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42:975-979, 2002
64. Mojaat N, Kaabi H, Hmida S, et al: Seroprevalence of HTLV-I/II antibodies in blood donors and different groups at risk in Tunisia. J Acq Immun Defic Synd 22:314-315, 1999
65. Vrielink H, Sisay Y, Reesink HW, et al: Evaluation of a combined lysate/recombinant antigen anti-HTLV-I/II ELISA in high and low endemic areas of HTLV-I/II infection. Transfusion Med 5:135-137, 1995
66. Nur YA, Groen J, Elmi AM, et al: Prevalence of serum antibodies against blood borne and sexually transmitted agents in selected groups in Somalia. Epidemiol Infect 124:137-141, 2000
67. Tabor E: Human T-lymphotropic virus types I and II in Africa in 1969. Transfusion 38:612-613, 1998
68. Melo J, Beby-Defaux A, Faria C, et al: HIV and HTLV prevalence among women seen for sexually transmitted diseases or pregnancy follow-up in Maputo, Mozambique. J AIDS 23:203-207, 2000
69. du Plessis R, Webber L, Saayman G: Bloodborne viruses in forensic medical practice in South Africa. Am J Forensic Med Pathol 20:364-368, 1999
70. Feng C, Yang J, Ruxin H, et al: Prevalence of antibodies to HTLV-I/II in blood donors and risk populations in South China. Vox Sang 75:154, 1998 (letter)
71. Geng L, Zai N, Xiao Y, et al: Search for human T-lymphotropic virus type I carriers among northeastern Chinese. J Dermatol Sci 18:30-34, 1998
72. Oguma S, Imamura Y, Kusumoto Y, et al: Stable human T-lymphotropic virus type I carrier rates for 7 years among a teenaged blood donor cohort of 1986 in Kumamoto, Japan. Leuk Res 19:567-571, 1995
73. Nakashima K, Kashiwagi S, Kajiyama W, et al: Sexual transmission of human T-lymphotropic virus type I among female prostitutes and among patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am J Epidemiol 141:305-311, 1995
74. Goto K, Sato K, Kurita M, et al: The seroprevalence of HTLV-I in patients with ocular disease, pregnant women and healthy volunteers in the Kanto district, central Japan. Scand J Infect Dis 29:219-221, 1997
75. Kim JM, Chang KH, Choi YH, et al: Seroprevalence of HTLV-I in Cheju Island, a Korean island adjacent to the endemic area of Japan. J AIDS 22:409-412, 1999
76. Kim JM, Song YG, Oho YC, et al: Antibodies to human T-cell lymphotropic virus type I (HTLV-I) by particle agglutination (PA) test in Korean blood donors. Yonsei Med J 40:173-177, 1999
77. Lu SC, Kao CL, Chin LT, et al: Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999. Int J Hematol 74:333-337, 2001
78. Chang CS, Wu YW, Pan YC, et al: Low prevalence of human T-cell lymphotropic virus type I infection among volunteer blood donors in Taiwan. Transfusion 38:1118-1119, 1998
79. Lucas RE, Faoagali JL: The serological status of Solomon Island blood donors. Southeast Asian J Trop Med Public Health 30:542-545, 1999
80. Furusyo N, Hayashi J, Kakuda K, et al: Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-I infections in selected Solomon Islands populations. Am J Trop Med Hyg 61:85-91, 1999
81. Tanggo Y, Gultom SP, Simanjuntak T, et al: Human T lymphotropic virus I in Indonesia. Very low seroprevalence in the Jakarta area: Antibodies in healthy blood donors and in various nonhematological diseases. Intervirology 43:77-79, 2000
82. Louisirirotchanakul S, Thongput A, Khamboonruang C, et al: No evidence of HTLV-I or HTLV-II infection among the Hmong people of northern Thailand or injecting drug users in Bangkok. J AIDS 23:441-442, 2000
83. Sawayama Y, Hayashi J, Ariyama I, et al: A ten year serological survey of hepatitis A, B and C viruses infections in Nepal. J Epidemiol 9:350-354, 1999
84. Ramalingam S, Kannangai R, Prakash KJ, et al: A pilot study of HTLV-1 infection in high-risk indiviuals and their family members from India. Indian J Med Res 113:201-209, 2001
85. Naman R, Klayme S, Naboulsi M, et al: HTLV-I and HTLV-II infections in volunteer blood donors high-risk groups in Lebanon. J Infect 45:29-31, 2002
86. Senyuta N, Syrtsev A, Yamashita M, et al: Seroepidemiologic and phylogenetic studies of HTLV-I infection in 2 countries of the Caspian Sea region. Int J Cancer 77:488-493, 1998
87. Arif M, Ramia S: Seroprevalence of human T-lymphotropic virus type I (HTLV-I) in Saudi Arabia. Ann Trop Med Parasitol 92:305-309, 1998
88. Tynell E, Andersson S, Lithander E, et al: Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: Cost effectiveness analysis. BMJ 315:1417-1422, 1998
89. Christensen PB, Krarup HB, Niesters HG, et al: Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 16:1043-1049, 2000
90. Nübling M: Human T-cell lymphocytotropic virus prevalence in German blood donors and "at-risk" groups. Vox Sang 81:204-206, 2001
91. Zaaijer HL, Lelie PN, van der Poel CL: Infection with T-lymphotropic virus in Dutch blood donors, 1993-1996 [Dutch article]. Ned Tijdschr Geneesk 141:1571-1572, 1997
92. Regan FAM, Hewitt P, Barbara JAJ, et al: TTI Study Group: Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood. BMJ 320: 403-406, 2000
93. Kurtz J, Smith N, Harbour S: HTLV-I is lower in blood donors in West Midlands than South Thames. BMJ 321:380-381, 2000
94. Price J, Cant BA, Barbara JAJ, et al: Human T-cell leukemia/lymphoma virus risk may be enhanced in some selected donor populations. Vox Sang 80:148-150, 2001
95. Dow BC, Munro H, Ferguson K, et al: HTLV antibody screening using mini-pools. Transfusion Med 11:419-422, 2001
96. Donati M, Seyedzadeh H, Leung T, et al: Prevalence of antibody to human T cell leukaemia/lymphoma virus in women attending antenatal clinic in southeast London: Retrospective study. BMJ 320:92-93, 2000
97. Ades AE, Parker S, Walker J, et al: Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: Population study. BMJ 320:1497-1501, 2000
98. Egan JF, O'Leary B, Lewis MJ, et al: High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. AIDS Res Hum Retroviruses 15:699-705, 1999
99. Courouce AM, Pillonel J, Lemaire JM, et al: Seroepidemiology of HTLV-I/ II in universal screening of blood donations in France. AIDS 7:841-847, 1993
100. Massari V, Elghouzzi MH, Agis F, et al: Epidemiologic comparison of human T-lymphotropic virus type 1-infected blood donors from endemic and nonendemic region over a 3-year period. Transfusion 34:198-201, 1994
101. Pillonel J, Saura C, Couroucé AM: Prévalence du VIH, de l'HTLV et des virus des hépatites B et C chez les donneurs de sang en France, 1992-1996. Transfusion Clin Biol 5:305-312, 1998
102. Couroucé AM, Pillonel J, Saura C: Dépistage des marqueurs des infections transmissibles par transfusion sur les dons collectés en France de 1996à; 1998. Transfusion Clin Biol 7:153-170, 2000
103. Toro C, Rodés B, Aguilera A, et al: Clinical impact of HTLV-I infection in Spain: Implications for public health and mandatory screening. J AIDS 30:366-368, 2002
104. Suligoi B, Galli C, Ciuta S, et al: Low seroprevalence of HTLV-I and HTLV-II in patients with a sexually transmitted disease. Study Group for HTLV and STDs. Eur J Epidemiol 15:225-229, 1999
105. Giuliani M, Rezza G, Lepri AC, et al: Risk Factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases. Sex Transm Dis 27:87-92, 2000
106. Poljak M, Bednaik J, Rednak K, et al: Seroprevalence of human T cell leukaemia/lymphoma virus type I (HTLV-I) in pregnant women, patients attending venereological outpatient services and intravenous drug use from Slovenia. Folia Biol (Praha) 44:23-25, 1998
107. Eble B, Busch MP, Guiltinan AM, et al: Determination of human T lymphotropic virus type by polymerase chain reaction and correlation with risk factors in northern California blood donors. J Infect Dis 167:954-957, 1993
108. Murphy EL, Watanabe K, Nass CC, et al: Evidence among blood donors for a 30-year old epidemic of human T lymphotropic virus type II infection in the United States. J Inf Dis 180:1777-1783, 1999
109. Watanabe KK, Williams AE, Schreiber GB, et al: for the Retrovirus Epidemiology Donor Study: Infectious disease markers in young blood donors. Transfusion 40:954-960, 2000
110. Telzak EE, Hershow R, Kalish LA, et al: Seroprevalence of HTLV-1 and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's inter-agency HIV study. J Acquir Immune Defic Syndr Hum Retrovirol 19:513-518, 1998
111. Peters AA, Coulthart MB, Oger JJF, et al: HTLV type I/II in British Columbia Amerindians: A seroprevalence study and sequence characterization of an HTLV type IIa isolate. AIDS Res Hum Retroviruses 16:883-892, 2000
112. Césaire R, Bera O, Maier H, et al: Seroindeterminate patterns and seroconversions to human T-lymphotropic virus type I positivity in blood donors from Martinique, French West Indies. Transfusion 39:1145-1149, 1999
113. Mansuy JM, Schlegel L, Villeneuve L, et al: Seroprevalence of retroviral infections among pregnant women in Martinique (French West Indies). Am J Trop Med Hyg 61:598-599, 1999
114. Rouet F, Foucher C, Rabie M, et al: Human T-lymphotropic virus type I among blood donors from Guadeloupe: Donation, demographic, and biologic characteristics. Transfusion 39:639-644, 1999
115. Kamphuis DJ, Martina IS, Keli SO, et al: Seroprevalence of human T-cell lymphotropic virus type I Curacao and predictive variables for that infection [article in Dutch]. Ned Tijdschr Geneeskd 142:89-92, 1998
116. Barton EN, King SD, Douglas LL: The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients. West Indian Med J 47:105-107, 1998
117. Plancoulaine S, Gessain A, Joubert M, et al: Detection of a major gene predisposing to human T lymphotropic virus type I infection in children among endemic population of African origin. J Infect Dis 182:405-412, 2000
118. Talarmin A, Vion B, Ureta-Vidal A, et al: First seroepidemiological study and phylogenetic characterization of human T-cell lymphotropic virus type I and II infection among Amerindians in French Guiana. J General Virology 80:3083-3088, 1999
119. Leon-Ponte M, Echeverria de Perez G, Bianco N, et al: Endemic infection with HTLV-IIB in Venezuelan Indians: Molecular characterization. J Acquir Immune Defic Syndr Hum Retrovirol 17:458-464, 1998
120. Fujiyoshi T, Li H-C, Lou H, et al: Characteristic distribution of HTLV type I and HTLV type II carriers among native ethnic groups in South America. AIDS Res Hum Retroviruses 15:1235-1239, 1999
121. Shindo N, Alcantara LCJ, van Dooren S, et al: Human retroviruses (HIV and HTLV) in Brazilian Indians: Seroepidemiological study and molecular epidemiology of HTLV type 2 isolates. America. AIDS Res Hum Retroviruses 18:71-77, 2002
122. Bittencourt AL, Dourado I, Filho PB, et al: Human T-cell lymphotropic virus type I infection among pregnant women in Northeastern Brazil. J AIDS 26:490-494, 2001
123. Brites C, Harrinton W Jr, Pedroso C, et al: Epidemiological characteristics of HTLV-I and II co-infection in Brazilian subjects infected by HIV-1. Braz J Infect Dis 1:42-47, 1997
124. Etzel A, Shibata GY, Rozman M, et al: HTLV-I and HTLV-2 infections in HIV-infected individuals from Santos, Brazil: Seroprevalence and risk factors. J AIDS 26:185-190, 2001
125. Guimaraes ML, Bastos FI, Telles PR, et al: Retrovirus infections in a sample of injecting drug users in Ria de Janeiro City, Brazil: Prevalence of HIV-I subtypes, and co-infection with HTLV-I/II. J Clin Virol 21:143-151, 2001
126. Gomes I, Melo A, Proietti FA, et al: Human T lymphotropic virus type I (HTLV-I) infection in neurological patients in Salvador, Bahia, Brazil. J Neurol Sci 165:84-89, 1999
127. Biglione M, Vidan O, Mahieux R, et al: Seroepidemiological and molecular studies of human T cell lymphotropic virus type II, subtype b, in isolated groups of Mataco and Toba Indians of Northern Argentia. AIDS Res Hum Retroviruses 15:407-417, 1999